Jennifer Turek Queally

Jennifer Turek Queally, PhD, is a neuropsychologist who sees patients in Boston Children’s Spina Bifida Program and the Neuropsychology Program. She also has clinical and research interests in the transition into adulthood and self regulation/executive functioning skill development. Dr. Queally is a supervisor in the predoctoral internship program and the neuropsychology postdoctoral residency program. She completed her fellowship in pediatric neuropsychology at Boston Children's in 2005 and is an Assistant Professor of Psychology at Harvard Medical School.

Although Dr. Queally worked closely with oncology patients for years, much of her clinical work has now transitioned to be with children who have neurodevelopmental disorders; many of her current patients were born with a medical condition or were affected shortly after birth, changing their developmental trajectory. She has a strong interest in facilitating functional independence; each child deserves to have a team working with them to help support their development over time and to reach their potential. She is honored to be included in the teams of so many of our patients.

Departments

• Department of Psychiatry and Behavioral Sciences

Programs

• Neuropsychology Program
• Spina Bifida and Spinal Cord Conditions Center

EDUCATION

Undergraduate Degree

• George Washington University , 1998 , Washington , DC

Graduate Degree

Clinical Psychology Suffolk University , 2003 , Boston , MA

Internship

Psychology Children's Hospital and Clinics , 2003 , Minneapolis , MN

Fellowship

Pediatrics Neuropsychology Boston Children's Hospital , 2005 , Boston , MA

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

• Neuropsychological care guidelines for people with spina bifida. J Pediatr Rehabil Med. 2020; 13(4):663-673.
• Validation of a bowel dysfunction instrument for adolescents with spina bifida. J Pediatr Urol. 2015 Aug; 11(4):199.e1-7.
• Neuropsychological outcomes of standard risk and high risk patients treated for acute lymphoblastic leukemia on Dana-Farber ALL consortium protocol 95-01 at 5 years post-diagnosis. Pediatr Blood Cancer. 2012 May; 58(5):758-65.
• Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. Pediatr Blood Cancer. 2011 Sep; 57(3):492-8.
• Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. J Clin Oncol. 2007 Nov 01; 25(31):4914-21.
• Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy therapy compared with 18 gray cranial radiation as CNS treatment in Acute Lymphoblastic Leukemia: Findings from Dana Farber Cancer Institute ALL Consortium Protocol 95-01. Journal of Clinical Oncology. 2007; 25(31):4914-4921.